Statements Of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities
Net loss	$ (4,921,766)	$ (26,517,688)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	989,501	1,095,613
Amortization	224,875	224,875
Amortization of warrants	1,978,264	995,926
Share-based compensation	1,979,159	1,741,184
Loss on asset disposal	4,122	83,705
Non-cash royalty (income), net		(2,353,718)
Adjustment of warrants and debt conversion features	(9,679,848)	(3,251,822)
Changes in operating assets and liabilities:
Accounts receivable	594,397	9,381,579
Other receivables	17,910	(5,719)
Inventories	(693,139)	(425,031)
Prepaid expenses and other current assets	(279,595)	246,982
Other assets	1,648	(3,284)
Accounts payable	(1,033,514)	(1,789,687)
Accrued liabilities	(560,126)	(813,483)
Deferred revenue	(660,196)	1,436,934
Other liabilities	(3,093)	(5,647)
Net cash used in operating activities	(12,041,401)	(19,959,281)
Cash flows from investing activities
Purchase of equipment	(130,103)	(972,881)
Net cash used in investing activities	(130,103)	(972,881)
Cash flows from financing activities
Payments of term note	(3,000,000)	(1,000,000)
Proceeds from revolving line of credit	42,246,305	52,309,376
Payments of revolving line of credit	(49,363,204)	(45,409,376)
Proceeds from subordinated convertible debt, net of issuance costs	7,738,351
Proceeds/Payments from Cowen Debt	2,500,000
Payments of Cowen Debt	(1,114,095)
Payments of Biosense Debt		(3,448,210)
Proceeds from issuance of stock and warrants, net of issuance costs	9,122,431	211,416
Net cash provided by financing activities	8,129,788	2,663,206
Net decrease in cash and cash equivalents	(4,041,716)	(18,268,956)
Cash and cash equivalents at beginning of period	13,954,919	35,248,819
Cash and cash equivalents at end of period	$ 9,913,203	$ 16,979,863